Table 1

Study eligibility criteria

CharacteristicsDetails of what will be considered
PopulationPeople with a new diagnosis of FIGO stage 3 and FIGO stage 4 endometrial cancer
InterventionNeoadjuvant chemotherapy or radiotherapy prior to surgery
ComparatorPrimary surgery followed by adjuvant chemotherapy or radiotherapy
OutcomesMain outcomes of interest
  • Overall survival

  • Progression free survival


Secondary outcomes
  • Completeness of cytoreduction

  • Patients who complete intended treatment

  • Adverse events

Timing
  • Overall survival and progression free survival at 5 years will be compared

  • Cytoreductive completeness at end of surgery will be compared

  • Proportion of patients receiving both treatments within 6 months of initiation of treatment

  • Adverse events up to 30 days of completing a treatment will be considered

  • Long-term side effects of treatments persisting after first 6 months after treatment

SettingProspective and retrospective studies from any country will be considered
  • FIGO, International federation of Gynecology and Obstetrics.